Cocrystal Pharma, Inc. balance sheet

At the end of fiscal 2020, Cocrystal Pharma, Inc. had total assets of $54.2m, total liabilities of $1.7m and shareholders' equity of $52.5m. It held $33.0m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cocrystal Pharma, Inc.: balance sheet, annual
Fiscal year	2011Dec 2011	2019Dec 2019	2020Dec 2020
Cash and equivalents	0	7	33
Receivables	1	1	1
Inventory	2	—	—
Total current assets	3	8	34
Goodwill	1	19	19
Total assets	8	29	54
Accounts payable	2	2	1
Total current liabilities	7	2	1
Short-term debt	0	—	—
Total debt	5	0	0
Total liabilities	—	3	2
Shareholders' equity	−3	26	53

US$ millions unless shown otherwise. Fiscal quarters.

Cocrystal Pharma, Inc.: balance sheet, quarterly
Quarter	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	1	1	1	1	1	1	—	—
Total current assets	7	8	23	20	33	34	6	3
Goodwill	65	19	19	19	19	19	—	—
Total assets	73	29	43	40	53	54	7	5
Accounts payable	1	2	1	1	1	1	1	2
Total current liabilities	2	2	2	3	3	1	2	3
Total liabilities	3	3	2	3	3	2	3	4
Shareholders' equity	71	26	40	37	50	53	4	1
Shares outstanding	32m	35m	52m	52m	69m	70m	14m	14m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cocrystal Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cocrystal Pharma, Inc.